Novavax is preparing an emergency use authorization application for its two-dose COVID-19 vaccine and likely will submit the full package to FDA by the end of the year, the company said Wednesday (Nov. 10), coming after the Centers for Disease Control and Prevention updated its travel guidance to say that people who received Novavax’s shot at certain non-U.S.-based clinical